<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151137</url>
  </required_header>
  <id_info>
    <org_study_id>EFC11405</org_study_id>
    <secondary_id>2010-019791-73</secondary_id>
    <secondary_id>U1111-1116-5566</secondary_id>
    <nct_id>NCT01151137</nct_id>
  </id_info>
  <brief_title>Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy</brief_title>
  <acronym>PALLAS</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  Demonstrate the efficacy of Dronedarone in preventing major cardiovascular events
           (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death) or
           unplanned cardiovascular hospitalization or death from any cause in patients with
           permanent Atrial Fibrillation [AF] and additional risk factors

      Secondary Objective:

        -  Demonstrate the efficacy of Dronedarone in preventing cardiovascular death

      This was an event-driven study where a common study end date [CSED] was to be determined by
      Steering Committee based on the number of events (stroke, systemic arterial embolism,
      myocardial infarction or cardiovascular death).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period per participant was variable depending on the enrollment in the study.

      A final follow-up visit had to occur within 1 month after the CSED.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped because of safety concerns
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overview of the Two Co-primary Outcomes</measure>
    <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
    <description>First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions [MI], or cardiovascular death.
Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause.
Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks [TIA], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to First Co-primary Outcome (Cumulative Incidence Function)</measure>
    <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
    <description>Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death.
Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.
95% confidence interval was computed at each time-point using Greenwood's variance estimation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Second Co-primary Outcome (Cumulative Incidence Function)</measure>
    <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
    <description>Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause.
Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.
95% confidence interval was computed at each time-point using Greenwood's variance estimation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deaths</measure>
    <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
    <description>Deaths were classified according to the primary cause of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cardiovascular Death (Cumulative Incidence Function)</measure>
    <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
    <description>Time to cardiovascular death was defined as the time from randomization to the death.
Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.
95% confidence interval was computed at each time-point using Greenwood's variance estimation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overview of Cardiovascular Events</measure>
    <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overview of Adverse Events [AE]</measure>
    <time_frame>from first study drug intake up to 10 days after the last study drug intake</time_frame>
    <description>AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3236</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dronedarone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dronedarone 400 mg twice a day until the CSED</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for Dronedarone) twice a day until the CSED</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronedarone</intervention_name>
    <description>Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)</description>
    <arm_group_label>Dronedarone</arm_group_label>
    <other_name>MULTAQ</other_name>
    <other_name>SR33589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Dronedarone)</intervention_name>
    <description>film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Permanent AF defined by the presence of all of the following criteria:

               -  Availability of one 12-lead ECG not more than 14 days prior to randomization
                  showing that the patient is in AF or atrial flutter;

               -  Availability of documentation (including either rhythm strips or medical report
                  of the rhythm) showing that the patient was in AF or atrial flutter at least 6
                  months prior to randomization;

               -  No evidence of sinus rhythm in the period between these two documentations of AF;

               -  Decision of the patient and physician to allow AF to continue without further
                  efforts to restore sinus rhythm.

          -  At least one of the following risk criteria:

               -  Coronary artery disease;

               -  Prior stroke or Transient Ischemic Attack [TIA];

               -  Symptomatic heart failure;

               -  Left ventricular ejection fraction [LVEF] less or equal to 0.40;

               -  Peripheral arterial occlusive disease;

               -  Aged 75 years or older with both hypertension and diabetes mellitus.

        Exclusion criteria:

          -  Paroxysmal AF;

          -  Persistent AF without a decision to allow AF to continue without further efforts to
             restore sinus rhythm;

          -  Heart failure of New-York Heart Association [NYHA] class IV or recent unstable NYHA
             class III.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Macquarie Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Providencia Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kallithea</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Lysaker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
    <country>India</country>
    <country>Kazakhstan</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </removed_countries>
  <results_reference>
    <citation>Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011 Dec 15;365(24):2268-76. doi: 10.1056/NEJMoa1109867. Epub 2011 Nov 14. Erratum in: N Engl J Med. 2012 Feb 16;366(7):672.</citation>
    <PMID>22082198</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2010</study_first_posted>
  <results_first_submitted>September 14, 2012</results_first_submitted>
  <results_first_submitted_qc>October 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 26, 2012</results_first_posted>
  <last_update_submitted>October 23, 2012</last_update_submitted>
  <last_update_submitted_qc>October 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment initiated in July 2010 was discontinued on July 6, 2011 upon recommendations of the Data Monitoring Committee due to an increased number of observed cardiovascular events in the Dronedarone group. The common study end date [CSED] was defined as July 15, 2011.
At that time 494 sites in 37 countries had enrolled at least one patient.</recruitment_details>
      <pre_assignment_details>Assignment to groups was done centrally using an Interactive Voice Response System [IVRS] or an Interactive Web Response System [IWRS] in a 1:1 ratio.
A total of 3236 participants were randomized at 489 sites (instead of 10800 as initially planned). The median duration of their participation in the study was 3.5 months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
        </group>
        <group group_id="P2">
          <title>Dronedarone</title>
          <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1617"/>
                <participants group_id="P2" count="1619"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="1610">One participant randomized to the placebo group received Dronedarone for 7 days by mistake</participants>
                <participants group_id="P2" count="1613"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued Treatment</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="342"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1601"/>
                <participants group_id="P2" count="1591"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
        </group>
        <group group_id="B2">
          <title>Dronedarone</title>
          <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1617"/>
            <count group_id="B2" value="1619"/>
            <count group_id="B3" value="3236"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.0" spread="5.9"/>
                    <measurement group_id="B2" value="75.0" spread="5.9"/>
                    <measurement group_id="B3" value="75.0" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="577"/>
                    <measurement group_id="B2" value="568"/>
                    <measurement group_id="B3" value="1145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1040"/>
                    <measurement group_id="B2" value="1051"/>
                    <measurement group_id="B3" value="2091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Regions were defined as follows:
North America: Canada, United States
South America: Argentina, Brazil, Chile, Mexico
Western Europe: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom
Eastern Europe: Bulgaria, Czech Republic, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine Asia: Hong Kong, Republic of Korea, Malaysia, Singapore, Taiwan Rest of the World: Australia, Israel, New zealand, South Africa</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="459"/>
                    <measurement group_id="B2" value="475"/>
                    <measurement group_id="B3" value="934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="495"/>
                    <measurement group_id="B2" value="488"/>
                    <measurement group_id="B3" value="983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rest of the word</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Permanent atrial fibrillation [AF] history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 months to 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="490"/>
                    <measurement group_id="B2" value="498"/>
                    <measurement group_id="B3" value="988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1124"/>
                    <measurement group_id="B2" value="1119"/>
                    <measurement group_id="B3" value="2243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CHADS2 Score</title>
          <description>CHADS2 is a risk-prediction score ranging from 0 to 6 used estimate Stroke Risk in Atrial Fibrillation patients.
CHADS2 score is obtained by adding together the points that correspond to the conditions that are present:
C: Congestive Heart Failure history: 1 point
H: Hypertension history: 1 point
A: Age ≥75 years: 1 point
D: Diabetes Mellitus history: 1 point
S: Stroke symptoms previously or Transient Ischemic Attack [TIA]: 2 points</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1444"/>
                    <measurement group_id="B2" value="1427"/>
                    <measurement group_id="B3" value="2871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unavailable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association [NYHA] class</title>
          <description>NYHA classification is a functional classification that places the patient in one of 4 categories, based on how much he/she is limited during physical activity:
Class I: no limitation of activities; the patient suffers no symptoms from ordinary activities.
Class II: slight, mild limitation of activity; the patient is comfortable with rest or with mild exertion.
Class III: marked limitation of activity; the patient is comfortable only at rest.
Class IV: complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No congestive heart failure [CHF]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="535"/>
                    <measurement group_id="B2" value="512"/>
                    <measurement group_id="B3" value="1047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="749"/>
                    <measurement group_id="B2" value="732"/>
                    <measurement group_id="B3" value="1481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overview of the Two Co-primary Outcomes</title>
        <description>First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions [MI], or cardiovascular death.
Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause.
Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks [TIA], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause.</description>
        <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
        <population>Intent-to-treat population: All randomized participants considered in the treatment group to which they were randomized regardless of the treatment they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
          </group>
          <group group_id="O2">
            <title>Dronedarone</title>
            <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Overview of the Two Co-primary Outcomes</title>
          <description>First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions [MI], or cardiovascular death.
Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause.
Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks [TIA], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause.</description>
          <population>Intent-to-treat population: All randomized participants considered in the treatment group to which they were randomized regardless of the treatment they actually received</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1617"/>
                <count group_id="O2" value="1619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First co-primary endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second co-primary endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to First Co-primary Outcome (Cumulative Incidence Function)</title>
        <description>Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death.
Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.
95% confidence interval was computed at each time-point using Greenwood’s variance estimation.</description>
        <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
        <population>Intent-to-treat population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
          </group>
          <group group_id="O2">
            <title>Dronedarone</title>
            <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Co-primary Outcome (Cumulative Incidence Function)</title>
          <description>Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death.
Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.
95% confidence interval was computed at each time-point using Greenwood’s variance estimation.</description>
          <population>Intent-to-treat population as previously defined</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1617"/>
                <count group_id="O2" value="1619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cumulative incidence at 14 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" lower_limit="0.000" upper_limit="0.004"/>
                    <measurement group_id="O2" value="0.009" lower_limit="0.005" upper_limit="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="0.000" upper_limit="0.006"/>
                    <measurement group_id="O2" value="0.013" lower_limit="0.008" upper_limit="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" lower_limit="0.003" upper_limit="0.012"/>
                    <measurement group_id="O2" value="0.021" lower_limit="0.014" upper_limit="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013" lower_limit="0.006" upper_limit="0.021"/>
                    <measurement group_id="O2" value="0.042" lower_limit="0.028" upper_limit="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 270 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" lower_limit="0.012" upper_limit="0.064"/>
                    <measurement group_id="O2" value="0.045" lower_limit="0.030" upper_limit="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 360 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" lower_limit="0.012" upper_limit="0.064"/>
                    <measurement group_id="O2" value="0.045" lower_limit="0.030" upper_limit="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As a consequence of the early termination of the study, the analysis was performed for information only without any adjustment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>A priori threshold for statistical significance: 0.05</p_value_desc>
            <method>Log Rank</method>
            <method_desc>2-sided Log-rank’s asymptotic test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.294</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.337</ci_lower_limit>
            <ci_upper_limit>3.936</ci_upper_limit>
            <estimate_desc>Hazard ratio (HR) of Dronedarone versus placebo for stroke, systemic arterial embolism, myocardial infarction or cardiovascular death
HR and confidence interval were estimated using Cox regression model with treatment group as the only factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Second Co-primary Outcome (Cumulative Incidence Function)</title>
        <description>Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause.
Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.
95% confidence interval was computed at each time-point using Greenwood’s variance estimation.</description>
        <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
        <population>Intent-to-treat population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
          </group>
          <group group_id="O2">
            <title>Dronedarone</title>
            <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Second Co-primary Outcome (Cumulative Incidence Function)</title>
          <description>Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause.
Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.
95% confidence interval was computed at each time-point using Greenwood’s variance estimation.</description>
          <population>Intent-to-treat population as previously defined</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1617"/>
                <count group_id="O2" value="1619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cumulative incidence at 14 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" lower_limit="0.002" upper_limit="0.008"/>
                    <measurement group_id="O2" value="0.020" lower_limit="0.013" upper_limit="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" lower_limit="0.008" upper_limit="0.020"/>
                    <measurement group_id="O2" value="0.034" lower_limit="0.025" upper_limit="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" lower_limit="0.023" upper_limit="0.042"/>
                    <measurement group_id="O2" value="0.069" lower_limit="0.055" upper_limit="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.059" lower_limit="0.043" upper_limit="0.075"/>
                    <measurement group_id="O2" value="0.110" lower_limit="0.089" upper_limit="0.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 270 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.099" lower_limit="0.062" upper_limit="0.137"/>
                    <measurement group_id="O2" value="0.137" lower_limit="0.107" upper_limit="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 360 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.099" lower_limit="0.062" upper_limit="0.137"/>
                    <measurement group_id="O2" value="0.137" lower_limit="0.107" upper_limit="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As a consequence of the early termination of the study, the analysis was performed for information only without any adjustment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A priori threshold for statistical significance: 0.05</p_value_desc>
            <method>Log Rank</method>
            <method_desc>2-sided Log-rank's asymptotic test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.947</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.448</ci_lower_limit>
            <ci_upper_limit>2.617</ci_upper_limit>
            <estimate_desc>Hazard ratio (HR) of Dronedarone versus placebo for unscheduled cardiovascular hospitalization or death from any cause
HR and confidence interval were estimated using Cox regression model with treatment group as the only factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deaths</title>
        <description>Deaths were classified according to the primary cause of death.</description>
        <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
        <population>Intent-to-treat population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
          </group>
          <group group_id="O2">
            <title>Dronedarone</title>
            <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Deaths</title>
          <description>Deaths were classified according to the primary cause of death.</description>
          <population>Intent-to-treat population as previously defined</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1617"/>
                <count group_id="O2" value="1619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Cardiovascular death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>--- Cardiac arrhythmic death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cardiovascular Death (Cumulative Incidence Function)</title>
        <description>Time to cardiovascular death was defined as the time from randomization to the death.
Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.
95% confidence interval was computed at each time-point using Greenwood's variance estimation.</description>
        <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
        <population>Intent-to-treat population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
          </group>
          <group group_id="O2">
            <title>Dronedarone</title>
            <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cardiovascular Death (Cumulative Incidence Function)</title>
          <description>Time to cardiovascular death was defined as the time from randomization to the death.
Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.
95% confidence interval was computed at each time-point using Greenwood's variance estimation.</description>
          <population>Intent-to-treat population as previously defined</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1617"/>
                <count group_id="O2" value="1619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cumulative incidence at 14 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" lower_limit="0.000" upper_limit="0.003"/>
                    <measurement group_id="O2" value="0.003" lower_limit="0.000" upper_limit="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" lower_limit="0.000" upper_limit="0.006"/>
                    <measurement group_id="O2" value="0.005" lower_limit="0.002" upper_limit="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" lower_limit="0.001" upper_limit="0.007"/>
                    <measurement group_id="O2" value="0.008" lower_limit="0.003" upper_limit="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 180 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" lower_limit="0.001" upper_limit="0.007"/>
                    <measurement group_id="O2" value="0.022" lower_limit="0.012" upper_limit="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 270 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" lower_limit="0.001" upper_limit="0.052"/>
                    <measurement group_id="O2" value="0.026" lower_limit="0.013" upper_limit="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cumulative incidence at 360 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" lower_limit="0.001" upper_limit="0.052"/>
                    <measurement group_id="O2" value="0.026" lower_limit="0.013" upper_limit="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>As a consequence of the early termination of the study, the analysis was performed for information only without any adjustment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0460</p_value>
            <p_value_desc>A priori threshold for statistical significance: 0.05</p_value_desc>
            <method>Log Rank</method>
            <method_desc>2-sided Log-rank's asymptotic test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.115</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.996</ci_lower_limit>
            <ci_upper_limit>4.490</ci_upper_limit>
            <estimate_desc>Hazard ratio (HR) of Dronedarone versus placebo for cardiovascular death
HR and confidence interval were estimated using Cox regression model with treatment group as the only factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overview of Cardiovascular Events</title>
        <time_frame>From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)</time_frame>
        <population>Intent-to-treat population as previously defined</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
          </group>
          <group group_id="O2">
            <title>Dronedarone</title>
            <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Overview of Cardiovascular Events</title>
          <population>Intent-to-treat population as previously defined</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1617"/>
                <count group_id="O2" value="1619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MI or unstable angina pectoris</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Ischemic stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic arterial embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Episode of heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Hospitalization due to heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unplanned hospitalization for cardiovascular cause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overview of Adverse Events [AE]</title>
        <description>AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
        <time_frame>from first study drug intake up to 10 days after the last study drug intake</time_frame>
        <population>Safety population: all randomized and treated participants. Participants were considered according to the treatment actually received. Consequently the participant randomized to the placebo group who received Dronedarone was included in the Dronedarone group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
          </group>
          <group group_id="O2">
            <title>Dronedarone</title>
            <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Overview of Adverse Events [AE]</title>
          <description>AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.</description>
          <population>Safety population: all randomized and treated participants. Participants were considered according to the treatment actually received. Consequently the participant randomized to the placebo group who received Dronedarone was included in the Dronedarone group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1609"/>
                <count group_id="O2" value="1614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600"/>
                    <measurement group_id="O2" value="797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Any serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Any AE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Any AE leading to treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Any AE leading to hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) were collected regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit.</time_frame>
      <desc>The analysis included all randomized participants who received at least one dose of study drug and all AE that developed or worsened from randomization up to 10 days after last study drug intake.
Participants were considered according to the treatment actually received regardless the amount of treatment administered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo twice daily until the CSED (median treatment duration of 87.5 days)</description>
        </group>
        <group group_id="E2">
          <title>Dronedarone</title>
          <description>Dronedarone 400 mg twice daily until the CSED (median treatment duration of 74 days)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Fungal peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Electrolyte depletion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Skin ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Eventration procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1609"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="1614"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months after trial completion, the investigator can present or publish trial results. A copy is submitted to the sponsor for review and comment at least 30 days in advance of any presentation or submission for publication.
The sponsor can require to delay the communication for a period not exceeding 90 days to allow for filing a patent application or such other measures as sponsor deems appropriate to establish and preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Given that the study was prematurely discontinued after 3236 patients were randomized (30% of the initial planned number), p-values were provided for information without any adjustment for multiplicity.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>Contact_US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

